L'Oréal has increased its stake in Galderma to 20%, deepening its strategic position in the medical-aesthetics and dermatology company. The move reflects L'Oréal's confidence in Galderma's portfolio—anchored by Restylane (HA filler), Dysport (abobotulinumtoxinA), and Sculptra (PLLA biostimulator)—and signals intent to leverage Galderma's distribution and clinical relationships across professional aesthetics and dermatology.
Business & M&A
L'Oréal Boosts Galderma Stake to 20% — Strategic Consolidation in Aesthetics
L'Oréal's increased investment signals confidence in Galderma's injectables and skincare portfolio amid competitive pressure.
1-YEAR MOVE
LRLCY
▲0.3%
ABBV
▲11.6%
EOLS
▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| LRLCY | L'Oréal (CeraVe · SkinCeuticals) | +0.3% |
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
| EOLS | Evolus | −15.6% |
L'Oréal raises its Galderma stake to 20%, signaling strategic confidence in the injectables and biostimulator portfolio.
For practice owners, L'Oréal's increased ownership underscores Galderma's competitive standing against AbbVie/Allergan Aesthetics and Revance in the injectables market. L'Oréal's beauty-and-wellness reach could accelerate Galderma's consumer-facing campaigns and retail partnerships, potentially shifting market dynamics around brand loyalty and rebate programs (Aspire, Evolus Rewards). The investment also signals that Galderma is unlikely to be acquired by a financial buyer in the near term—L'Oréal's stake functions as a strategic anchor. Practice owners should monitor whether L'Oréal's ownership translates into pricing pressure or margin compression on Restylane and Dysport.
Source: original report ↗
Frequently asked questions
What products does Galderma make that practices use?
Galderma's core injectables portfolio includes Restylane (hyaluronic acid filler), Dysport (abobotulinumtoxinA), and Sculptra (PLLA biostimulator). These are among the most widely used products in aesthetic practices for wrinkle reduction and facial volumization.
Why did L'Oréal increase its stake in Galderma to 20%?
L'Oréal's increased investment signals confidence in Galderma's injectables and skincare portfolio and reflects strategic intent to leverage Galderma's distribution and clinical relationships across professional aesthetics and dermatology. The move also positions L'Oréal to accelerate consumer-facing campaigns and retail partnerships in the medical-aesthetics space.
Does L'Oréal's ownership of Galderma mean it will be acquired?
L'Oréal's 20% stake functions as a strategic anchor that makes acquisition by a financial buyer unlikely in the near term. The investment signals L'Oréal's intent to maintain and grow Galderma as an operating company rather than sell it off.
How does L'Oréal's Galderma stake affect pricing and margins for practices?
Practice owners should monitor whether L'Oréal's ownership translates into pricing pressure or margin compression on Restylane and Dysport. L'Oréal's consumer-facing reach and potential retail partnerships could shift market dynamics around brand loyalty and rebate programs like Aspire and Evolus Rewards.
How does Galderma compete against other injectables companies?
Galderma competes directly against AbbVie/Allergan Aesthetics and Revance in the injectables market. L'Oréal's increased ownership underscores Galderma's competitive standing and suggests confidence in its ability to hold and grow market share.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.